{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:27:17Z","timestamp":1792945637362,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Expanded access to antiretroviral therapy (ART) leads to improved HIV\/AIDS treatment outcomes in Nigeria, however, increasing rates of loss to follow-up among those on ART is threatening optimal standard achievement. Therefore, this retrospective cross-sectional study is aimed at identifying correlates and predictors of loss to follow-up in patients commencing ART in a large HIV program in Nigeria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Records of all patients from 432 US CDC Presidents Emergency Plan for AIDS Relief (PEPFAR) supported facilities across 10 States and FCT who started ART from 2004 to 2017 were used for this study. Bivariate and multivariate analysis of the demographic and clinical parameters of all patients was conducted using STATA version 14 to determine correlates and predictors of loss to follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Within the review period, 245,257 patients were ever enrolled on anti-retroviral therapy. 150,191 (61.2%) remained on treatment, 10,960 (4.5%) were transferred out to other facilities, 6926 (2.8%) died, 2139 (0.9%) self-terminated treatment and 75,041 (30.6%) had a loss to follow-up event captured. Males (OR: 1.16), Non-pregnant female (OR: 4.55), Patients on\u2009\u2265\u20093-monthly ARV refills (OR: 1.32), Patients with un-suppressed viral loads on ART (OR: 4.52), patients on adult 2nd line regimen (OR: 1.23) or pediatric on 1st line regimen (OR: 1.70) were significantly more likely to be lost to follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite increasing access to anti-retroviral therapy, loss to follow-up is still a challenge in the HIV program in Nigeria. Differentiated care approaches that will focus on males, non-pregnant females and paediatrics is encouraged. Reducing months of Anti-retroviral drug refill to less than 3\u00a0months is advocated for increased patient adherence.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-019-0241-3","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T13:07:56Z","timestamp":1570540076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Predictors of loss to follow-up in art experienced patients in Nigeria: a 13\u00a0year review (2004\u20132017)"],"prefix":"10.1186","volume":"16","author":[{"given":"Ahmad","family":"Aliyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde","family":"Adelekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nifarta","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Ekong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dapiap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fati","family":"Murtala-Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iboro","family":"Nta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dakum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"241_CR1","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/QAI.0b013e3182167f0d","volume":"57","author":"P Braitstein","year":"2011","unstructured":"Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Walusuna L, Ayaya S, Nyandiko W, Yiannoutsos C. \u201cWamepotea\u201d (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57:e40\u20136. https:\/\/doi.org\/10.1097\/QAI.0b013e3182167f0d .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"241_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-3156.2010.02508.x","volume":"15","author":"MP Fox","year":"2010","unstructured":"Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007\u20132009: systematic review. Trop Med Int Health. 2010;15:1\u201315. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02508.x .","journal-title":"Trop Med Int Health"},{"key":"241_CR3","doi-asserted-by":"publisher","first-page":"e1001111","DOI":"10.1371\/journal.pmed.1001111","volume":"8","author":"BH Chi","year":"2011","unstructured":"Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, Brinkhof MWG, Mwango A, Balestre E, Carriquiry G, Sirisanthana T, Mukumbi H, Martin JN, Grimsrud A, Bacon M, Thiebaut R. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8:e1001111. https:\/\/doi.org\/10.1371\/journal.pmed.1001111 .","journal-title":"PLoS Med."},{"key":"241_CR4","first-page":"272","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organisation","year":"2013","unstructured":"World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. New York: WHO; 2013. p. 272."},{"key":"241_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/QAI.0b013e3181b843f0","volume":"53","author":"EH Geng","year":"2010","unstructured":"Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405\u201311. https:\/\/doi.org\/10.1097\/QAI.0b013e3181b843f0 .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"241_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-3156.2010.02507.x.Tracking","volume":"15","author":"EH Geng","year":"2010","unstructured":"Geng EH, Bangsberg R, Martin JN. Tracking a sample of patients LTFU has a major impact on understanding determinants of survival in HIV\u2009=\u2009infected patients on ART in Africa. Trop Med Int Health. 2010;15:63\u20139. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02507.x.Tracking .","journal-title":"Trop Med Int Health"},{"key":"241_CR7","unstructured":"UNAIDS, Global AIDS Update 2018, Geneva, 2018."},{"key":"241_CR8","unstructured":"UNAIDS, Nigeria| HIV and AIDS estimates, Geneva, 2016."},{"key":"241_CR9","unstructured":"WHO, Nigeria aligns national protocol to WHO \u201cTreat All\u201d guidelines on HIV\/AIDS prevention and treatment-, Abuja, 2016."},{"key":"241_CR10","unstructured":"FMOH, National Guidelines for HIV Prevention Treatment and Care, Abuja, 2016."},{"key":"241_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11604\/pamj.2015.22.139.4981","volume":"22","author":"O Babatunde","year":"2015","unstructured":"Babatunde O, Ojo OJ, Atoyebi OA, Ekpo DS, Ogundana AO, Olaniyan TO, Owoade JA. Seven year review of retention in HIV care and treatment in federal medical centre Ido-Ekiti. Pan Afr Med J. 2015;22:1\u20139. https:\/\/doi.org\/10.11604\/pamj.2015.22.139.4981 .","journal-title":"Pan Afr Med J."},{"key":"241_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0140746","volume":"10","author":"S Janssen","year":"2015","unstructured":"Janssen S, Wieten RW, Stolp S, Cremers AL, Rossatanga EG, Klipstein-Grobusch K, Belard S, Grobusch MP. Factors associated with retention to care in an HIV clinic in Gabon, central Africa. PLoS ONE. 2015;10:1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0140746 .","journal-title":"PLoS ONE"},{"key":"241_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11904-010-0061-5.Retention","volume":"7","author":"EH Geng","year":"2011","unstructured":"Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, Muyindike W, Bwana MB, Yiannoutsos CT, Petersen ML, Martin JN. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV\/AIDS Rep. 2011;7:234\u201344. https:\/\/doi.org\/10.1007\/s11904-010-0061-5.Retention .","journal-title":"Curr HIV\/AIDS Rep."},{"key":"241_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2155-6113.1000393","volume":"5","author":"K Tadesse","year":"2014","unstructured":"Tadesse K. Fisiha H. ARC study, predictors of loss to follow up of patients enrolled on antiretroviral therapy. 2014;5:2. https:\/\/doi.org\/10.4172\/2155-6113.1000393 .","journal-title":"ARC study, predictors of loss to follow up of patients enrolled on antiretroviral therapy."},{"key":"241_CR15","first-page":"2004","volume":"898","author":"SG Agolory","year":"2017","unstructured":"Agolory SG, Auld AF, Odafe S, Shiraishi RW, Dokubo K, Swaminathan M, Dalhatu I, Onotu D, Abiri O, Debem H, Bashorun A, Ellerbrock TV. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in. 2017;898:2004\u201312.","journal-title":"High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in"},{"key":"241_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0165528","volume":"11","author":"I Dalhatu","year":"2016","unstructured":"Dalhatu I, Onotu D, Odafe S, Abiri O, Debem H, Agolory S, Shiraishi RW, Auld AF, Swaminathan M, Dokubo K, Ngige E, Asadu C, Abatta E, Ellerbrock TV. Outcomes of Nigeria\u2019s HIV\/AIDS treatment program for patients initiated on antiretroviral treatment between 2004\u20132012. PLoS ONE. 2016;11:1\u201325. https:\/\/doi.org\/10.1371\/journal.pone.0165528 .","journal-title":"PLoS ONE"},{"key":"241_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.15.2.17424","volume":"15","author":"S Odafe","year":"2012","unstructured":"Odafe S, Idoko O, Badru T, Aiyenigba B, Suzuki C, Khamofu H, Onyekwena O, Okechukwu E, Torpey K, Chabikuli ON. Patients\u2019 demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:1\u20139. https:\/\/doi.org\/10.7448\/IAS.15.2.17424 .","journal-title":"J Int AIDS Soc."},{"key":"241_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11604\/pamj.2013.15.35.2198","volume":"15","author":"B Saka","year":"2013","unstructured":"Saka B, Landoh DE, Patassi A, d\u2019Almeida S, Singo A, Gessner BD, Pitch\u00e9 PV. Loss of HIV-infected patients on potent antiretroviral therapy programs in Togo: risk factors and the fate of these patients. Pan Afr Med J. 2013;15:1\u20137. https:\/\/doi.org\/10.11604\/pamj.2013.15.35.2198 .","journal-title":"Pan Afr Med J."},{"key":"241_CR19","first-page":"1","volume":"56","author":"R Arnesen","year":"2017","unstructured":"Arnesen R, Moll AP, Shenoi SV. Predictors of loss to follow-up among patients on ART at a rural hospital in KwaZulu-Natal, South Africa. PLoS ONE. 2017;56:1\u201312.","journal-title":"PLoS ONE"},{"key":"241_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-3156.2010.02505.x.Low","volume":"15","author":"C Amani-bosse","year":"2011","unstructured":"Amani-bosse C, Minga A, Messou E, Sow PS. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres. Trop Med Int Heal. 2011;15:34\u201342. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02505.x.Low .","journal-title":"Trop Med Int Heal."},{"key":"241_CR21","doi-asserted-by":"publisher","first-page":"e003499","DOI":"10.1136\/bmjopen-2013-003499","volume":"3","author":"BL H\u00f8nge","year":"2013","unstructured":"H\u00f8nge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, Ostergaard L, Laursen AL, Wejse C. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;3:e003499. https:\/\/doi.org\/10.1136\/bmjopen-2013-003499 .","journal-title":"BMJ Open."},{"key":"241_CR22","doi-asserted-by":"publisher","first-page":"e5790","DOI":"10.1371\/journal.pone.0005790","volume":"4","author":"MW Brinkhof","year":"2009","unstructured":"Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE. 2009;4:e5790. https:\/\/doi.org\/10.1371\/journal.pone.0005790 .","journal-title":"PLoS ONE."},{"key":"241_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2334-11-31","volume":"11","author":"R Weigel","year":"2011","unstructured":"Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, Mhango E, Nkwazi B, Tweya H, Kamlaka M, Chagwera F, Phiri S. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis. 2011;11:31. https:\/\/doi.org\/10.1186\/1471-2334-11-31 .","journal-title":"BMC Infect Dis."},{"key":"241_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/gha.v6i0.21682","volume":"6","author":"G Alvarez-Uria","year":"2013","unstructured":"Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. Glob Health Action. 2013;6:1\u20138. https:\/\/doi.org\/10.3402\/gha.v6i0.21682 .","journal-title":"Glob Health Action."},{"issue":"2","key":"241_CR25","doi-asserted-by":"publisher","first-page":"031","DOI":"10.1093\/ofid\/ofx031","volume":"4","author":"PA Agaba","year":"2017","unstructured":"Agaba PA, Meloni ST, Sule HM, Agbaji OO, Sagay AS, Okonkwo P, Idoko JA, Kanki PJ. Treatment outcomes among older human immunodeficiency virus-infected adults in Nigeria. Open Forum Infect Dis. 2017;4(2):031.","journal-title":"Open Forum Infect Dis."},{"key":"241_CR26","doi-asserted-by":"crossref","unstructured":"K.G. Marson, Loss to Follow-up in an urban African antiretroviral treatment clinic, A Thesis MPH, 2012.","DOI":"10.1371\/journal.pone.0078900"},{"key":"241_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2471\/BLT.09.064329","volume":"88","author":"V Ochieng-Ooko","year":"2010","unstructured":"Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, Yiannoutsos CT, Owiti M, Kimaiyo S, Braitstein P. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681\u20138. https:\/\/doi.org\/10.2471\/BLT.09.064329 .","journal-title":"Bull World Health Organ"},{"key":"241_CR28","doi-asserted-by":"publisher","DOI":"10.1179\/2047773211Y.0000000018","author":"CA Onoka","year":"2012","unstructured":"Onoka CA, Uzochukwu BS, Onwujekwe OE, Chukwuka C, Ilozumba J, Onyedum C, Nwobi EA, Onwasigwe C. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. 2012. https:\/\/doi.org\/10.1179\/2047773211Y.0000000018 .","journal-title":"Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria"},{"key":"241_CR29","doi-asserted-by":"crossref","unstructured":"Press D. Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region. 2016. p. 83\u201392.","DOI":"10.2147\/HIV.S98137"},{"key":"241_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2652-13-49","volume":"13","author":"AT Brennan","year":"2010","unstructured":"Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010;13:1\u201310. https:\/\/doi.org\/10.1186\/1758-2652-13-49 .","journal-title":"J Int AIDS Soc"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-019-0241-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T06:21:19Z","timestamp":1664605279000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-019-0241-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["241"],"URL":"https:\/\/doi.org\/10.1186\/s12981-019-0241-3","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institution\u2019s (Institute of Human Virology, Nigeria) Research Ethics Committee and is covered by the NHREC approval for program evaluation. The data reviewed and presented in this study were originally collected in the medical record of each of the facilities involved as part of routine medical care\/program activities. Informed consent was not required from patients since recording of data into the medical charts\/database was for regular medical care and program implementation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}